UK Markets open in 3 hrs 41 mins

Compass Therapeutics, Inc. (CMPX)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.5000-0.0500 (-1.41%)
At close: 2:10PM EDT

Compass Therapeutics, Inc.

80 Guest Street
Suite 601
Boston, MA 02135
United States
617 500 8099
http://www.compasstherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees31

Key executives

NameTitlePayExercisedYear born
Dr. Thomas J. Schuetz Ph.D.Co-Founder, CEO & Director4kN/A1961
Dr. Vered Bisker-Leib Ph.D., MBAPres & COO520kN/A1971
Mr. Neil L. Lerner CPAVP of Fin.N/AN/A1967
Dr. Susan Kalled Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corporate governance

Compass Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.